Pertussis immunization in the Global Pertussis Initiative European Region: Recommended strategies and implementation considerations

Pediatric Infectious Disease Journal

Volumn 24, Issue 5 SUPPL., 2005, Pages

  Von König, Carl Heinz Wirsing ^a   Campins Marti, Magda ^b   Finn, Adam ^e   Guiso, Nicole ^e   Mertsola, Jussi ^d   Liese, Johannes ^c  

^a Klinikum Krefeld   (Germany)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e NONE

Author keywords

Adolescents; Bordetella pertussis; Europe; Health care workers; Immunization; Pertussis

Indexed keywords

ACELLULAR VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE; INACTIVATED VACCINE; POLIOMYELITIS VACCINE;

EUROPE; HEALTH CARE PERSONNEL; HUMAN; INFANT MORTALITY; MORBIDITY; PERTUSSIS; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 18744406308     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000160920.75623.a3     Document Type: Review

References (34)

1. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA. 1998;280:635-637.
2. Baron S, Njamkepo E, Grimpel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J. 1998;17:412-418.
3. Gil A, Oyaguez I, Carrasco P, Gonzalez A. Hospital admissions for pertussis in Spain, 1995-1998. Vaccine. 2001;19:4791-4794.
4. de Melker HE, Schellekens JFP, Nepplenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis. 2000;6:348-357.
5. Van Buynder PG, Owen D, Vurdien JE, Andrews NJ, Matthews RC, Miller E. Bordetella pertussis surveillance in England and Wales: 1999. Epidemiol Infect. 1999;123:403-411.
6. Gilberg S, Njamkepo E, Parent du Chalet I, et al. Evidence of Bordetella pertussis infection in adults presenting with persistent cough in a French area with very high whole-cell vaccine coverage. J Infect Dis. 2002;186:415-418.
7. Lieberman D, Shvartzman P, Lieberman D, et al. Etiology of respiratory tract infection in adults in a general practice setting. Eur J Clin Microbiol Infect Dis. 1998;17:685-689.
8. Crowcroft NS, Booy R, Harrison T, et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child. 2003;88:802-806.
9. Guiso N. Pertussis: a current disease: epidemiology and physiopathology. Rev Mal Respir. 1999;16(suppl 3):169-170.
10. Forsyth K, Tan T, Wirsing von König CH, Caro J, Plotkin S. Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J. 2005;24(suppl):S69-S74.
11. Edwards K, Decker MD, Mortimer EA Jr. Pertussis vaccine. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3 ed. Philadelphia, PA: W. B. Saunders; 1999:293-344.
12. EC Directive 2000/54/EC. 111:4:3.
13. Forsyth K, Nagai M, Lepetic A, Trindade E. Pertussis immunization in the Global Pertussis Initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J. 2005;24(suppl):S93-S97.
14. Tan T, Halperin S, Cherry JD, et al. Pertussis immunization in the Global Pertussis Initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J. 2005;24(suppl):S83-S86.
15. Wirsing von König CH, Riffelmann M, Juretzko P, Laubereau B, von Kries R. Relevanz verzögerter impfungen gegen Pertussis [in German]. Kinderarztl Prax. 2002;7:468-473.
16. Blakely TA, Mansoor O, Baker M. The 1996 pertussis epidemic in New Zealand: vaccine effectiveness. NZ Med J. 1999;112:118-119.
17. de Melker HE, Conyn-van Spaendonck MAE, Rümke HC, van Wijngaarden JK, Mooi FR, Schellekens JFP. Pertussis in the Netherlands: an outbreak despite high levels of immunization with whole-cell vaccine. Emerg Infect Dis. 1997;3:175-178.
18. Fine PEM, Clarkson JA. Reflections on the efficacy of pertussis vaccines. Rev Infect Dis. 1987;9:866-883.
19. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. BMJ. 1988;296:612-614.
20. Lambert HJ. Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep. 1965;80:365-390.
21. Cattaneo LA, Reed GW, Haase DH, Willos MJ, Edwards KM. The seroepidemiology of Bordetella pertussis infections: a study of persons aged 1 to 65 years. J Infect Dis. 1996;173:1256-1259.
22. Rehmet S, Ammon A, Pfaff G, Bocter N, Petersen LR. Cross-sectional study on influenza vaccination, Germany, 1999-2000. Emerg Infect Dis. 2002;8:1442-1447.
23. Empfehlungen der Staendigen Impfkommision am Robert-Koch-Insitut. Epidemiol Bull. 2003;32:245-260.
24. de Melker HE, Versteegh FG, Conyn-Van Spaendonck MA, et al. Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol. 2000;38:800-806.
25. Marchant CD, Loughlin AM, Lett SM, et al. Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis. 1994;169:1297-1305.
26. Wirsing von König CH, Gounis D, Laukamp S, Bogaerts H, Schmitt HJ. Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Eur J Clin Microbiol Infect Dis. 1999;18:341-345.
27. EN 15189 (ISO 15189:2003).
28. Edmunds WJ, Brisson M, Melagaro A, Gay NJ. Potential cost-effectiveness of acellular pertussis booster vaccination in England and Wales. Vaccine. 2002;20:1316-1330.
29. Schmitt H-J, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H. Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis. 2003;3:103-108.
30. Heininger U, Stehr K, Schmidt-Schlaepfer G, et al. Bordetella pertussis infections and sudden unexpected deaths in children. Eur J Pediatr. 1996;155:551-553.
31. Lindgren C, Milerad J, Lagercrantz H. Sudden infant death and prevalence of whooping cough in the Swedish and Norwegian communities. Eur J Pediatr. 1997;156:405-409.
32. Taranger J, Trollfors B, Lagergard T, et al. Correlation between pertussis toxin IgG antibodies in post vaccination and subsequent protection against pertussis 2000. J Infect Dis. 2000;181:1010-1013.
33. Lugauer S, Heininger U, Cherry JD, Stehr K. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr. 2002;161:142-146.
34. Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001;108:E81.